Luminex and Bio-Rad Extend Their Global Sales and Distribution Agreement to 2023
News Apr 05, 2012
Luminex Corporation has announced that it has extended its global sales and distribution agreement with Bio-Rad Laboratories, Inc. to 2023.
In addition, Luminex has granted Bio-Rad global sales and distribution rights for Luminex's award-winning MAGPIX multiplexing instrument.
As part of the agreement, Bio-Rad will now offer the full range of Luminex's xMAP® systems including the MAGPIX system, a compact, flexible instrument that simultaneously detects up to 50 different analytes (including proteins and nucleic acids) on a single sample quickly, accurately and reproducibly.
"We are very pleased to extend our sales and distribution agreement and to have Bio-Rad as a global distribution partner for MAGPIX," said Michael F. Pintek, senior vice president of operations at Luminex.
Pintek continued, "As a leader in the life science research market, Bio-Rad can provide researchers additional access for this highly innovative instrument that offers a broad range of applications. Together we can accelerate the pace of research and advance healthcare for people around the world."
"We are looking forward to offering MAGPIX to our customers as part of a complete product offering featuring our analysis software and extensive assay menu," said Brad Crutchfield, Bio-Rad vice president and group manager Life Science Group.
Crutchfield continued, "This partnership with Luminex reflects Bio-Rad's ongoing commitment to providing the global research community with innovative technologies that will lead to scientific discovery and improved healthcare."
Protein's Role in Mitochondrial Metabolism IdentifiedNews
EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.READ MORE
Proteasome Blocker Brings Glaucoma Gene Therapy CloserNews
An enhanced gene therapy technique that pairs a viral vector with a proteasome blockade has doubled the therapy's efficiency.READ MORE